Journal
JOURNAL OF CLINICAL MEDICINE
Volume 10, Issue 17, Pages -Publisher
MDPI
DOI: 10.3390/jcm10173806
Keywords
antifibrotic agents; DMARDs; interstitial lung disease; rheumatoid arthritis; therapy
Categories
Ask authors/readers for more resources
RA is a common autoimmune arthritis, with ILD being the most important comorbidity. The acute form should be promptly treated with high-dose corticosteroids and antimicrobial agents, while the chronic form requires stabilization of RA followed by ILD management. Identification of UIP pattern and consideration of anti-fibrotic agents are crucial in patient care.
Rheumatoid arthritis (RA) is a common type of autoimmune arthritis. Patient clinical outcomes might be influenced by numerous respiratory diseases, but interstitial lung disease (ILD) is the most important comorbidity. RA-associated ILD (RA-ILD) is divided into acute/subacute and chronic forms. In the acute/subacute course, if the disease is severe as indicated by a diffuse alveolar damage pattern, high-dose corticosteroids combined with antimicrobial agents should be promptly initiated while considering the differential diagnoses, primarily acute exacerbation (AE) of RA-ILD, drug-induced pneumonitis, and Pneumocystis pneumonia. As initial therapeutic management in the chronic course, the RA itself should be stabilized without delay; thereafter, the activity of ILD itself can be stabilized, considering the safety of each anti-rheumatic drug. The formation of the usual interstitial pneumonia (UIP) pattern is the most important determinant because lung function can worsen more quickly with this pattern. However, because clinicians can fail to identify specific radiological patterns, it is important to determine whether each patient with RA-ILD has UIP-like lesions such as subpleural reticulation, traction bronchiectasis, and honeycombing especially progressively enlarged cysts. In patients with progressive RA-ILD and high risk for infection or AE of ILD in whom fibrosis is dominant, clinicians should consider starting an anti-fibrotic agent.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available